ResearcherUniversity of Alabama at BirminghamNo recent work listed

Seifeldin Awad

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-1787-6696; OpenAlex author ID A5113988250. Sources: OpenAlex.

Their work

Papers: 2
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 8

Papers, trials and grants by year

2020: 1 paper · 2021: none · 2022: 1 paper

Papers 2

Does race affect the long-term survival benefit of systemic therapy in pancreatic adenocarcinoma? Co-author DOI 10.1016/j.amjsurg.2022.04.004 ↗
Biochemical Predictors of Response to Neoadjuvant Therapy in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3389/fonc.2020.00620 ↗

Closest collaborators

The 8 strongest of 8 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

John Bart Rose · 2 shared papers, 2020–2022 · strength 0.29
- Paper Biochemical Predictors of Response to Neoadjuvant Therapy in Pancreatic Ductal Adenocarcinoma. DOI 10.3389/fonc.2020.00620 ↗
- Paper Does race affect the long-term survival benefit of systemic therapy in pancreatic adenocarcinoma? DOI 10.1016/j.amjsurg.2022.04.004 ↗
Ahmad Mahmoud Alkashash · 1 shared paper, 2020 · strength 0.15
- Paper Biochemical Predictors of Response to Neoadjuvant Therapy in Pancreatic Ductal Adenocarcinoma. DOI 10.3389/fonc.2020.00620 ↗
Selwyn Maurice Vickers · 1 shared paper, 2022 · strength 0.15
- Paper Does race affect the long-term survival benefit of systemic therapy in pancreatic adenocarcinoma? DOI 10.1016/j.amjsurg.2022.04.004 ↗
Ahmer Irfan · 1 shared paper, 2022 · strength 0.15
- Paper Does race affect the long-term survival benefit of systemic therapy in pancreatic adenocarcinoma? DOI 10.1016/j.amjsurg.2022.04.004 ↗
Olumide B. Gbolahan · 1 shared paper, 2022 · strength 0.15
- Paper Does race affect the long-term survival benefit of systemic therapy in pancreatic adenocarcinoma? DOI 10.1016/j.amjsurg.2022.04.004 ↗
Sushanth Reddy · 1 shared paper, 2022 · strength 0.15
- Paper Does race affect the long-term survival benefit of systemic therapy in pancreatic adenocarcinoma? DOI 10.1016/j.amjsurg.2022.04.004 ↗
Hua Amanda Fang · 1 shared paper, 2022 · strength 0.15
- Paper Does race affect the long-term survival benefit of systemic therapy in pancreatic adenocarcinoma? DOI 10.1016/j.amjsurg.2022.04.004 ↗
Vikas Dudeja · 1 shared paper, 2022 · strength 0.15
- Paper Does race affect the long-term survival benefit of systemic therapy in pancreatic adenocarcinoma? DOI 10.1016/j.amjsurg.2022.04.004 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.